Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences

Rhea-AI Summary

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) to participate in upcoming investor conferences.

SAN DIEGO--(BUSINESS WIRE)-- Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at the following upcoming investor conferences:

• Citi's 18^th Annual BioPharma Conference
  Date: Wednesday, September 6, 2023
  Location: Boston, MA
  Format: 1x1 Meetings

• Morgan Stanley 21^st Annual Global Healthcare Conference
  Date/Time: Tuesday, September 12, 2023 at 12:15 p.m. Eastern Time
  Location: New York, NY
  Format: Fireside Chat and 1x1 Meetings

• TD Cowen’s 3rd Annual Novel Mechanisms in Neuropsychiatry Summit
  Date/Time: Wednesday, September 20, 2023 at 5:00 p.m. Eastern Time
  Location: Virtual
  Format: Fireside Chat

• Cantor Fitzgerald Global Healthcare Conference
  Date/Time: Tuesday, September 26, 2023 at 11:30 a.m. Eastern Time
  Location: New York, NY
  Format: Fireside Chat and 1x1 Meetings

Live webcasts of Acadia’s presentations at the Morgan Stanley, Cantor Fitzgerald and TD Cowen conferences will be accessible on the company’s website, www.acadia.com, under the investors section and an archived recording will be available on the website for approximately one month following the presentation. 

About Acadia Pharmaceuticals

Acadia is advancing breakthroughs in neuroscience to elevate life. For 30 years we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only approved therapies for hallucinations and delusions associated with Parkinson’s disease psychosis and for the treatment of Rett syndrome. Our clinical-stage development efforts are focused on treating the negative symptoms of schizophrenia, Prader-Willi syndrome, Alzheimer’s disease psychosis and neuropsychiatric symptoms in central nervous system disorders. For more information, visit us at www.acadia.com and follow us on LinkedIn and Twitter.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230823759521/en/

Media Contact:

Acadia Pharmaceuticals Inc.

Deb Kazenelson

(818) 395-3043

media@acadia-pharm.com

Investor Contact:

Acadia Pharmaceuticals Inc.

Jessica Tieszen

(858) 261-2950

ir@acadia-pharm.com

 

Source: Acadia Pharmaceuticals Inc.